The 53 references in paper A. Smirnov V., V. Dobronravov A., I. Kayukov G., A. Bodur-OOrzhak Sh.-O., A. Essaian M., A. Kucher G., А. Смирнов В., В. Добронравов А., И. Каюков Г., А. Бодур-Ооржак Ш.-О., А. Есаян М., А. Кучер Г. (2006) “ЭПИДЕМИОЛОГИЯ И СОЦИАЛЬНО-ЭКОНОМИЧЕСКИЕ АСПЕКТЫ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК // EPIDEMIOLOGY AND SOCIAL-ECONOMICAL ASPECTS OF CHRONIC KIDNEY DISEASE” / spz:neicon:nefr:y:2006:i:1:p:7-13

1
European Best Practice Guidelines, Expert Group on Hemodialysis, European Renal Association. Section I. Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant 2002; 17[Suppl 7]: 7-15
(check this in PDF content)
2
Смирнов АВ. Хроническая болезнь почек или хроническое заболевание почек? Нефрология 2004; 8(1): 101-102
(check this in PDF content)
3
Смирнов АВ, Есаян АМ, Каюков ИГ. Хроническая болезнь почек: на пути к единству представлений. Нефрология 2002; 6(4): 11-17
(check this in PDF content)
4
Смирнов АВ, Каюков ИГ, Есаян АМ и др. Превентивный подход в современной нефрологии. Нефрология 2004; 8(3): 7-14
(check this in PDF content)
5
Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9(3): 7-15
(check this in PDF content)
6
Земченков АЮ, Томилина НА. «К/ДОКИ» обращается к истокам хронической почечной недостаточности (О новом разделе Рекомендаций K/DOQI по диагностике, классификации и оценке тяжести хронических заболеваний почек). Нефрология и диализ 2004; 6(3): 204-220
(check this in PDF content)
7
Томилина НА, Бикбов БТ. Эпидемиология хронической почечной недостаточности и новые подходы к классификации и оценке тяжести хронических прогрессирующих заболеваний почек. Тер арх 2005; 77(6): 87-92
(check this in PDF content)
8
Locatelli F, Del Vecchio L, Pozzoni P. The importance of early detection of chronic kidney disease. Nephrol Dial Transplant 2002; 17[Suppl 11]: 2-7
(check this in PDF content)
9
Norris K, Vaughn C. The role of renin-angiotensinaldosterone system in chronic kidney disease. Expert Rev Cardiovasc Ther 2003; 1(1): 51-63
(check this in PDF content)
10
Schiepati A, Remuzzi G. Chronic renal disease as a public health problem: Epidemiology, social and economic implications. Kidney Int 2005; 68[Suppl 98]: S7-S10
(check this in PDF content)
11
Jones CA, McQuillan GM, Kusek JW et al. Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998; 32: 992-999
(check this in PDF content)
12
National Kidney Foundation KD: Clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 2002; 39[Suppl 1]: S1-S266
(check this in PDF content)
13
Ritz E, Dikow R, Ruilope LM. Renal dysfunction as a cardiovascular risk factor. Curr Hypertens Rep 2002; 4: 365368
(check this in PDF content)
14
Stuveling EM, Bakker SJ, Hilige HX et al. Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol Dial Transplant 2005; 20: 497- 508
(check this in PDF content)
15
Halimi JM, Forhan A, Balkan B et al. Ig microalbuminuria an integrated risk marker for cardiovascular disease and insulin resistance in both men and women? J Cardiovasc Risk 2001; 8: 139- 146
(check this in PDF content)
16
Orth SR. Smoking and the kidney. J Am Soc Nephrol 2002; 13: 1663- 1672
(check this in PDF content)
17
Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41(1): 1-12
(check this in PDF content)
18
Chen J, Munter P, Hamm LZ et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004; 140: 167-174
(check this in PDF content)
19
Verhave JC, Gansevoort RT, Hillege HL et al. for the PREVEND Study Group. An elevated urinary albumin excretion predicts de novo development of renal function impairment in general population. Kidney Int 2004; 66 [Suppl 92]: S18-S21
(check this in PDF content)
20
Atkins RC. The epidemiology of chronic kidney disease. Kidney Int 2005; 67[94]: S14-S18
(check this in PDF content)
21
Iseki K, Iseki C, Ikemmiya Y et al. Risk of development of end-stage renal disease in a cohort mass screening. Kidney Int 1996; 49: 800-805
(check this in PDF content)
22
Мухин НА, Балкаров ИМ, Моисеев СВ и др. Хронические прогрессирующие нефропатии и образ жизни современного человека. Тер арх 2004; 76(9): 5-10
(check this in PDF content)
23
Бикбов БТ, Томилина НА. О состоянии заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 2001 г. (Отчет по данным регистра Российского диализного общества). Нефрология и диализ 2004; 6(1): 4-42
(check this in PDF content)
24
Добронравов ВА, Смирнов АВ, Драгунов СВ и др. Эпидемиология хронической болезни почек в Вологодской области. Нефрология 2004; 8(1): 36-41
(check this in PDF content)
25
Добронравов ВА, Смирнов АВ, Драгунов СВ и др. Эпидемиология хронической почечной недостаточности в Северо-Западном регионе России: на пути к созданию регистра хронической почечной болезни. Тер арх 2004; 76(9): 57-61
(check this in PDF content)
26
К проблеме лечения терминальной хронической почечной недостаточности в России. Первые итоги работы по созданию Российского национального регистра заместительной почечной терапии. Нефрология и диализ 1999;. 1(1): 79-84
(check this in PDF content)
27
Смирнов АВ, Добронравов ВА, Бодур-Ооржак АШ и др. Эпидемиология и факторы риска хронических болезней почек: региональный уровень общей проблемы. Тер арх 2005; (6): 20-27
(check this in PDF content)
28
Смирнов АВ, Добронравов ВА, Бодур-Ооржак АШ и др. Распространенность и заболеваемость поздними стадиями хронической болезни почек в Республике Тыва. Нефрология 2005; 9(4): 25-29
(check this in PDF content)
29
U.S. Renal Data System. USRDR 2004 Annual Data Report, Bethesda, MD, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2004
(check this in PDF content)
30
Moeller S, Gioberge S, Brown G. ESRD patients in 2001: Global overview of patients, treatment modalities and development trends. Nephrol Dial Transplant 2002; 17: 20712076
(check this in PDF content)
31
Locatelli F, Pozzoni P, Del Vecchio L. Epidemiology of chronic kidney disease in Italy: Possible therapeutical approaches. J Nephrol 2003; 16: 1-10
(check this in PDF content)
32
Locatelli F, Valderrabano F, Hoenich N et al. Progress in dialysis technology: membrane selection and patient outcome. Nephrol Dial Transplant 2000; 15: 1133-1139
(check this in PDF content)
33
Locatelli F, Marcelli D, Conte F et al. For the Registro Lombardo Dialisi e Trapianto. Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol Dial Transplant 2000; 15[Suppl 5]: S69-S80
(check this in PDF content)
34
Jones CA, Krolewski AS, Rogus J et al. Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int 2005; 67(5): 1684-1691
(check this in PDF content)
35
Mcclellan WM, Ramirez SPB, Jurkovitz C. Screening of chronic kidney disease: Unresolved question. J Am Soc Nephrol 2003; 14: S81-S87
(check this in PDF content)
36
Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12: 2753-2758
(check this in PDF content)
37
Rosansky SJ, Jackson K. Rate of change of end-stage renal disease treatment incidence 1978-1987- has there been selection? J Am Soc Nephrol 1992; 2(10): 1502-1506
(check this in PDF content)
38
Bommer J. Prevalence and socio-economic aspects of chronic kidney disease. Nephrol Dial Transplant 2002;. 17[Suppl]: 11; 8-12
(check this in PDF content)
39
Yap HK, Quek CM, Shen Q et al. Role of urinary screening programmes in children in the prevention of chronic kidney disease. Ann Acad Med Singapore 2005; 34: 3-7
(check this in PDF content)
40
Murakami M, Hayakawa M, Yanagihara T, Hukunaga Y. Proteinuria screening for children. Kidney Int 2005; [Suppl 94]: S23-S27
(check this in PDF content)
41
Murakami M, Yamamoto H, Ueda I et al. Urinary screening of elementary and junior high-school children over a 13-year period in Tokyo. Pediatr Nephrol 1991; 5: 50-53
(check this in PDF content)
42
Смирнов АВ, Есаян АМ, Каюков ИГ, Кучер АГ. Концепция хронической болезни почек в педиатрии. Нефрология 2005; 9(1): 13-18
(check this in PDF content)
43
Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002; 13 [Suppl 1]: S37-S40
(check this in PDF content)
44
Berthoux F, Jones E, Gellert R et al. Epidemiological data of treated end-stage renal failure in the European Union (EU) during the year 1995; Report of European Renal Association Registry and the National Registries. Nephrol Dial Transplant 1999; 14: 2332-2342
(check this in PDF content)
45
Rutkowski B. Changing pattern of end-stage renal failure in Central and Eastern Europe. Nephrol Dial Transplant 2002; 15: 156-160
(check this in PDF content)
46
Vecchi AF, Drratwa M, Weidemann ME. Healthcare system and end-stage renal disease (ESRD) therapies – an international review. Costs and reimbursement/funding of ERSD therapies. Nephrol Dial Transplant 1999; 14 [Suppl 6]: 31-41
(check this in PDF content)
47
Sakhuja V, Sub K. End-sage renal disease in India and Pakistan: Burden of disease and management issues. Kidney Int 2003; 63 [Suppl 83]: 115-118
(check this in PDF content)
48
Seng WK, Hwang SJ, Han DC et al. Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective. Nephrology (Carlton). 2005; 10(5): 520-524
(check this in PDF content)
49
Remuzzi G, Ruggenenti P, Perna A et al. RENAAL Study Group Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 2004; 15(12): 31173125
(check this in PDF content)
50
zucs TD, Sandoz MS, Keusch GW. The costeffectiveness of losartan in type 2 diabetics with nephropathy in Switzerland—an analysis of the RENAAL study. Swiss Med Wkly 2004; 134 (31-32): 440-447
(check this in PDF content)
51
Herman WH, Shahinfar S, Carides GW et al. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care 2003; 26(3): 683-687
(check this in PDF content)
52
Burgess ED, Carides GW, Gerth WC et al. Canadian Hypertension Society. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective. Can J Cardiol 2004; 20(6): 613-618
(check this in PDF content)
53
Lin CY, Sheng CC, Chen CH et al. The prevalence of heavy proteinuria and progression risk factors in children undergoing urinary screening. Pediatr Nephrol 2002; 14: 953959 Ïîñòóïèëà â ðåäàêöèþ 11.01.2006 ã.
(check this in PDF content)